Descripción

Study design overview for the trial evaluating human milk oligosaccharide (HMO) supplementation effects on gut microbiota and metabolite profiles in irritable bowel syndrome patients.

Figure 1

Flowchart

Source Paper

The Effects of Human Milk Oligosaccharides on Gut Microbiota, Metabolite Profiles and Host Mucosal Response in Patients with Irritable Bowel …

Nutrients (2021)

PMID: 34836092

DOI: 10.3390/nu13113836

Cite This Figure

![Figure 1: Study design overview for the trial evaluating human milk oligosaccharide (HMO) supplementation effects on gut microbiota and metabolite profiles in irritable bowel syndrome patients.]()

> Source: Cristina Iribarren et al. "The Effects of Human Milk Oligosaccharides on Gut Microbiota, Metabolite Profile." *Nutrients*, 2021. PMID: [34836092](https://pubmed.ncbi.nlm.nih.gov/34836092/)

<figure>
  <img src="" alt="Study design overview for the trial evaluating human milk oligosaccharide (HMO) supplementation effects on gut microbiota and metabolite profiles in irritable bowel syndrome patients." />
  <figcaption>Figure 1. Study design overview for the trial evaluating human milk oligosaccharide (HMO) supplementation effects on gut microbiota and metabolite profiles in irritable bowel syndrome patients.<br>  Source: Cristina Iribarren et al. "The Effects of Human Milk Oligosaccharides on Gut Microbiota, Metabolite Profile." <em>Nutrients</em>, 2021. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/34836092/">34836092</a></figcaption>
</figure>

Evidencia relacionada

Bifidobacterium longum para Irritable Bowel Syndrome (IBS)

Calificación B · 4 estudios

Galactooligosaccharides (GOS) para Irritable Bowel Syndrome (IBS)

Calificación B · 3 estudios